This white paper from Premier Research looks at how adaptive trial design is limiting the number of patients exposed to ineffective treatments and accelerating detection of efficacy signals in precision oncology research.
| This week's Fierce Biotech is brought to you by Premier Research.
Trouble viewing? Click here. |
| How Precision Medicine Is Changing the Way Early-Phase Oncology Studies Are Conducted |
|
| The emergence of precision medicine is driving a shift in how early-phase oncology trials are conducted. A growing number of Phase 1 trials are reporting preliminary response rates, a trend that reflects an increase in the use of adaptive trial designs that limit the number of patients exposed to ineffective treatments and accelerate the timeline to detection of efficacy signals.
Download Premier Research’s new white paper Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines for a closer look at how these designs can help you improve the efficiency and flexibility of your study. Topics include: The current state of precision medicine in oncology drug research Operational elements to consider, starting with whether to include a control group Common adaptive design strategies in precision oncology drug development Premier Research. Built for Biotech℠ DOWNLOAD NOW
|
|
|
|
| Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.
Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017 |
